NRX Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, announced the filing of a patent application for NRX-100, its preservative-free intravenous ketamine formulation designed for the treatment of suicidal depression. This formulation avoids the use of benzethonium chloride, a compound linked to potential toxicity concerns in existing ketamine formulations. The patent application, which includes twenty claims related to pharmaceutical compositions, treatment methods, and manufacturing processes, is currently under review by the US Patent and Trademark Office. If granted, it would provide exclusivity for NRX-100 until 2045 and could potentially be listed in the FDA Orange Book. This development strengthens NRx Pharmaceuticals' leadership in advancing safe and effective treatments for suicidal depression. The company remains on track to complete its New Drug Application submission this quarter, following the recent FDA fee waiver.